AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $46.41 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $45.55, a 22.55% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $58.81, a 40.49% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $41.86, a 23.57% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $54.77, a 20.18% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $46.06, a 18.10% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $39.00, a 30.48% decline from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $56.10, a 7.90% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $60.91, a 2.85% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.41 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $45.55 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | $46.06 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $49.37 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $45.29 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | $58.81 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $39.00 10-K · filed 2025-02-13 | |||
| 2024-09-30 | $42.18 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $41.52 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $41.86 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $56.10 10-K · filed 2024-02-15 | |||
| 2023-09-30 | $55.49 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $56.55 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $54.77 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $60.91 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $63.40 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $68.38 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $68.62 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $62.70 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $62.20 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $61.89 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $56.04 10-Q · filed 2021-04-29 | |||
| 2020-12-31 | $66.48 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $65.98 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $70.26 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $69.00 10-Q · filed 2020-04-30 | |||
| 2019-12-31 | $68.36 10-K · filed 2020-02-19 | |||
| 2019-09-30 | $67.59 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $66.38 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $64.12 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $76.26 10-K · filed 2019-02-14 | |||
| 2018-09-30 | $76.15 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | $75.98 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $88.78 10-Q · filed 2018-05-04 | |||
| 2017-12-31 | $74.48 10-K · filed 2018-02-14 | |||
| 2017-09-30 | $72.43 10-Q · filed 2017-11-01 | |||
| 2017-06-30 | $72.39 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $66.24 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $65.21 10-K · filed 2017-02-16 | |||
| 2016-09-30 | $68.27 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $73.33 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $75.17 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $73.77 10-K · filed 2016-02-26 | |||
| 2015-09-30 | $43.94 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $39.61 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $13.22 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $12.75 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $4.45 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $2.34 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $1.99 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |